From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
2-(2-Hydroxybenzoyl)oxybenzoic acid
Clinical data
Trade names Disalcid, Salflex
AHFS/ monograph
MedlinePlus a682880
Pregnancy cat. C (US)
Legal status -only (US)
CAS number 552-94-3 YesY
ATC code N02BA06
PubChem CID 5161
DrugBank DB01399
ChemSpider 4977 N
KEGG D00428 N
Chemical data
Formula C14H10O5 
Mol. mass 258.23 g/mol
 N (what is this?)  (verify)

Salsalate is a non-steroidal anti-inflammatory drug (NSAID). Salsalate is in a class of drugs called salicylates. Salsalate may work by inhibiting the production of and release of prostaglandins. Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[1]

Typical use[edit]

Salsalate is used to reduce pain and inflammation caused by conditions such as rheumatoid arthritis, osteoarthritis, and related rheumatic conditions. Salsalate is also recommended by physicians as an anti-inflammatory alternative to naproxen, and ibuprofen for patients that have had minor stomach bleeding or stomach upset. It has also been used as an alternative to narcotic pain medicine for people with spinal disc protrusion.

"In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo." [2]

Research on use to prevent or treat type II diabetes[edit]

Salsalate has been suggested to prevent or treat type II diabetes: "In a 20-patient, month-long study, the fasting glucose levels of those who took salsalate declined 13% compared with those who took a placebo. The results, published in the Feb. issue of Diabetes Care, suggest that the drug reduces blood sugar in obese adults who don’t have diabetes, apparently by making insulin work better."[3] Salsalate had been suggested as possible treatment for diabetes as early as 1876.[4][5] The anti-inflammatory property of salsalate may reverse the chronic inflammation thought to be the cause of diabetes in the obese.[4]

On March 20, 2010, The Joslin Diabetes Center, Boston, MA, released a report entitled: Generic Drug for Type 2 Diabetes Passes Next Clinical Hurdle - "Salsalate, an anti-inflammatory agent, shows encouraging results in preliminary trial"[6]


  1. ^ Salsalate entry
  2. ^ DrugBank: DB01399 (Salsalate)
  3. ^ Aspirin cousin could help prevent diabetes
  4. ^ a b Kendall Powell (May 31, 2007). "The Two Faces of Fat". Nature 447 (7144): 525–7. doi:10.1038/447525a. PMID 17538594. 
  5. ^ Ebstein, W (1876). "Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben". Berliner Klinische Wochenschrift 13: 337–340. 
  6. ^ Generic Drug for Type 2 Diabetes Passes Next Clinical Hurdle